Traffic Roots Audience Pixel

Cybin (NYSE: CYBN)

Mental illness doesn’t exist in a vacuum – it impacts those who suffer and the people around them. One in four people will be affected by mental illness at some point in their lives, and those caring for someone with mental illness will experience anxiety or depression at a higher rate.

Our team’s ambition is to improve the lives of those suffering from mental illness by changing the expectation of treatment. Today’s treatment options focus on managing symptoms, versus healing the underlying condition, often with unpleasant side effects and low rates of success.

Psychedelic therapies offer a novel approach to mental healthcare, focused on treating the underlying conditions and improving the patient experience and outcome. A paradigm shift in public policy has opened the door to new research and development in the field of psychedelic medicine and treatment regimens.

Cybin is at the forefront of this revolution. We believe that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape. While psychedelics may represent a new industry, we recognize the long history of use within indigenous cultures and major scientific breakthroughs over the decades that have led us to where we are today.